Effectiveness of influenza vaccines in children aged 6 to 59 months: a test-negative case-control study at primary care and hospital level, Spain 2023/24.
Gloria Pérez-Gimeno, Clara Mazagatos, Nicola Lorusso, Luca Basile, Isabel Martínez-Pino, Francisca Corpas Burgos, Noa Batalla Rebolla, Mercedes B Rumayor Zarzuelo, Blanca Andreu Ivorra, Jaume Giménez Duran, Daniel Castrillejo, Inés Guiu Cañete, Marta Huerta Huerta, Marta García Becerril, Violeta Ramos Marín, Inmaculada Casas, Francisco Pozo, Susana Monge
{"title":"Effectiveness of influenza vaccines in children aged 6 to 59 months: a test-negative case-control study at primary care and hospital level, Spain 2023/24.","authors":"Gloria Pérez-Gimeno, Clara Mazagatos, Nicola Lorusso, Luca Basile, Isabel Martínez-Pino, Francisca Corpas Burgos, Noa Batalla Rebolla, Mercedes B Rumayor Zarzuelo, Blanca Andreu Ivorra, Jaume Giménez Duran, Daniel Castrillejo, Inés Guiu Cañete, Marta Huerta Huerta, Marta García Becerril, Violeta Ramos Marín, Inmaculada Casas, Francisco Pozo, Susana Monge","doi":"10.2807/1560-7917.ES.2024.29.40.2400618","DOIUrl":null,"url":null,"abstract":"<p><p>During 2023/24, all children aged 6 to 59 months were targeted for seasonal influenza vaccination in Spain nationally. Using a test-negative case-control design with sentinel surveillance data, we estimated adjusted influenza vaccine effectiveness (IVE) against any influenza type to be 70% (95% confidence interval (CI): 51 to 81%) for primary care patients with acute respiratory illness (ARI) and 77% (95% CI: 21 to 93%) for hospitalised patients with severe ARI. In primary care, where most subtyped viruses (61%; 145/237) were A(H1N1), adjusted IVE was 77% (95% CI: 56 to 88%) against A(H1N1)pdm09.</p>","PeriodicalId":12161,"journal":{"name":"Eurosurveillance","volume":"29 40","pages":""},"PeriodicalIF":9.9000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11451132/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Eurosurveillance","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2807/1560-7917.ES.2024.29.40.2400618","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0
Abstract
During 2023/24, all children aged 6 to 59 months were targeted for seasonal influenza vaccination in Spain nationally. Using a test-negative case-control design with sentinel surveillance data, we estimated adjusted influenza vaccine effectiveness (IVE) against any influenza type to be 70% (95% confidence interval (CI): 51 to 81%) for primary care patients with acute respiratory illness (ARI) and 77% (95% CI: 21 to 93%) for hospitalised patients with severe ARI. In primary care, where most subtyped viruses (61%; 145/237) were A(H1N1), adjusted IVE was 77% (95% CI: 56 to 88%) against A(H1N1)pdm09.
期刊介绍:
Eurosurveillance is a European peer-reviewed journal focusing on the epidemiology, surveillance, prevention, and control of communicable diseases relevant to Europe.It is a weekly online journal, with 50 issues per year published on Thursdays. The journal includes short rapid communications, in-depth research articles, surveillance reports, reviews, and perspective papers. It excels in timely publication of authoritative papers on ongoing outbreaks or other public health events. Under special circumstances when current events need to be urgently communicated to readers for rapid public health action, e-alerts can be released outside of the regular publishing schedule. Additionally, topical compilations and special issues may be provided in PDF format.